Article Text

Download PDFPDF

Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials
  1. Jin-Tai Yu1,
  2. Wei Xu2,
  3. Chen-Chen Tan2,
  4. Sandrine Andrieu3,
  5. John Suckling4,
  6. Evangelos Evangelou5,
  7. An Pan6,
  8. Can Zhang7,
  9. Jianping Jia8,
  10. Lei Feng9,
  11. Ee-Heok Kua9,
  12. Yan-Jiang Wang10,
  13. Hui-Fu Wang2,
  14. Meng-Shan Tan2,
  15. Jie-Qiong Li2,
  16. Xiao-He Hou2,
  17. Yu Wan2,
  18. Lin Tan2,
  19. Vincent Mok11,
  20. Lan Tan2,
  21. Qiang Dong1,
  22. Jacques Touchon12,
  23. Serge Gauthier13,
  24. Paul S Aisen14,
  25. Bruno Vellas15
  1. 1 Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
  2. 2 Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
  3. 3 Department of Epidemiology and Public Health, University of Toulouse III, Toulouse, France
  4. 4 Department of Psychiatry, Medical Research Council and Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
  5. 5 Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece
  6. 6 Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  7. 7 Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
  8. 8 Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China
  9. 9 Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
  10. 10 Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, China
  11. 11 Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
  12. 12 Department of Neurology, University Hospital of Montpellier, Montpellier, France
  13. 13 McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada
  14. 14 Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA
  15. 15 Department of Geriatrics, Purpan University Hospital, Toulouse, France
  1. Correspondence to Professor Jin-Tai Yu, Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China; jintai_yu{at}


Background Evidence on preventing Alzheimer’s disease (AD) is challenging to interpret due to varying study designs with heterogeneous endpoints and credibility. We completed a systematic review and meta-analysis of current evidence with prospective designs to propose evidence-based suggestions on AD prevention.

Methods Electronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OPSs) and randomised controlled trials (RCTs) were included. The multivariable-adjusted effect estimates were pooled by random-effects models, with credibility assessment according to its risk of bias, inconsistency and imprecision. Levels of evidence and classes of suggestions were summarised.

Results A total of 44 676 reports were identified, and 243 OPSs and 153 RCTs were eligible for analysis after exclusion based on pre-decided criteria, from which 104 modifiable factors and 11 interventions were included in the meta-analyses. Twenty-one suggestions are proposed based on the consolidated evidence, with Class I suggestions targeting 19 factors: 10 with Level A strong evidence (education, cognitive activity, high body mass index in latelife, hyperhomocysteinaemia, depression, stress, diabetes, head trauma, hypertension in midlife and orthostatic hypotension) and 9 with Level B weaker evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C). In contrast, two interventions are not recommended: oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B).

Interpretation Evidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.

  • alzheimer's disease
  • epidemiology
  • meta-analysis
  • systematic reviews

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


An unequivocal downtrend in the prevalence and incidence of dementia was recently reported and associated with earlier population-level investment (eg, improved education and vascular health),1–3 strengthening the necessity for primary prevention.4 The past few decades have witnessed great global efforts in updating and upgrading the evidence on how to prevent Alzheimer’s disease (AD),5 6 accounting for approximately two-thirds of all cases of dementia and affecting up to 20% of individuals older than 80 years.7 8 Nevertheless, key issues in the field are the inconsistency among conclusions and variable levels of credibility arising from the wide variety of study designs.9 Two types of studies are generally regarded as having the greatest impact on the extant literature: (1) observational prospective studies (OPSs), which describe temporal relationships with potential causal links and often use large samples recruited from community dwellers; and (2) randomised controlled trials (RCTs), which possess strong internal validity to infer causality by testing the effects of specific interventions on the incidence of AD. Although both approaches are useful, the major concerns in OPSs are usually the elusive sources of bias when interpreting the identified wide-ranging factors, and current RCTs are often compromised by short follow-up durations, subjective endpoints, small sample sizes and specific recruitment criteria with uncertain generalisability.5

Considerable evidence has been generated regarding AD through OPSs and RCTs. Because it is almost impossible to conduct RCTs that evaluate all risk factors of AD, a quantitative depiction of AD’s prevention 'profile' based on these two complementary study types is urgently needed for prevention guidelines that weigh the benefits against the risks. Deconstructing the bias sources from OPSs will facilitate the interpretation of credibility ratings and also guide future research directions. In this study we consolidated the extant evidence from both OPSs and RCTs to formulate the levels of evidence and classes of clinical suggestions for AD prevention.


Search strategy and selection criteria

We followed the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2009 guidelines.10 11 PubMed, EMBASE and CENTRAL were searched using the terms “Alzheimer’s”, “Alzheimer”, “dementia”, and “risk” for OPS and “Alzheimer”, “cognitive”, “cognition”, “prevent”, and “prevention” for RCT up to 1 March 2019. Bibliographies of relevant literature and records in and AlzRisk database12 were hand-searched in case of omission. The inclusion criteria were as follows: (1) an OPS exploring the association between potentially modifiable exposures at baseline and incident AD independently diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria,13 or (2) a RCT targeting the impact of addressing modifiable risk factors on the incidence of AD or AD-related clinical endpoints (dementia or cognitive impairment), and (3) a publication written in English to permit easy access to the source information of all included articles. The detailed exclusion criteria are shown in figure 1. Bibliographies of relevant original studies and systematic reviews were hand-searched. Literature selection was performed by three pairs of experienced investigators (JTY, WX, CCT, HFW, MST and JQL) and any disagreements on inclusion were resolved by consensus and arbitration by a panel of investigators within the review team (JTY, WX, CCT, HFW, MST, JQL and Lan Tan).

Figure 1

Flow chart showing literature selection for OPSs (figure 1A) and RCTs (figure 1B) and map depicting studies eligible for systematic review (figure 1C). A total of 243 OPSs (figure 1A) and 153 completed RCTs (figure 1B) were finally included. 243 OPSs from 17 countries on four continents (Europe accounting for 43%, North America 41%, Asia 14% and Latin America 2%) reported the association of 134 modifiable risk factors with risk of clinical Alzheimer’s-type dementia (83% used all AD, 13% probable AD and 11% pure AD) diagnosed by NINCDS-ADRDA criteria in populations with various racial backgrounds (68% white, 14% Asian descent, 13% mixed race), sources (84% community, 6% institution, 10% mixed source) and baseline cognitive statuses (82% free of dementia, 16% cognitively normal, 2% unclear). A total of 153 published RCTs from five continents (North America accounting for 45%, Europe 36%, Australia 9%, Asia 7% and Latin America 3%) reported the effects of 15 types of interventions on AD (7%), dementia (16%) and cognitive function (85%) in selected participants, including elderly subjects (37%), high-risk group (35%) or cognitively impaired (28%) (figure 1C). In the pie charts, 1 and 2 show the outcome (all AD=probable or possible AD, or AD with or without VD/CVD, Pure AD=AD without VD or CVD; A=Alzheimer’s disease, B=Biomarker of AD, C=Cognition, D=Dementia); 3 and 4 show the population source; 5 and 6 show the percentage of studies from different continents. AD, Alzheimer’s disease; CVD, cerebrovascular disease; OPS, observational prospective study; RCT, randomised controlled trial; VD, vascular dementia.

Data extraction

Pre-designed templates were used to extract the data with reference to the STROBE statement ( An evidence-based profile of AD modifiable risk factors was established for better tracing of bias sources. The multivariable-adjusted risk estimates were extracted. If these estimates were unavailable, we attempted to obtain them by contacting the corresponding authors. The stringently performed process comprised three independent steps: (a) data extraction by three pairs of experienced investigators (JTY, WX, CCT, HFW, MST and JQL); (b) independent data proof reading by 10 researchers (JTY, WX, CCT, HFW, MST, JQL, XHH, YW, Lin Tan and Lan Tan); and (c) addressing discrepancies by consensus and arbitration.

Assessment of study quality and credibility of meta-analyses

The risk of bias tool proposed by Cochrane14 for RCTs and involving the Newcastle–Ottawa Quality Assessment Scale (NOS)15 for OPSs were used to evaluate the quality of eligible studies. The total score for the Cochrane tool or NOS was regarded as a proxy to assess the overall risk of bias for each single study. The score for each item evaluated the associated risk of bias (online supplementary appendix 1). The credibility of each meta-analysis result was then categorised into four levels: Good (G level), Acceptable (A± level), Susceptible (S± level) and Poor (P level) according to the score combination of three domains: risk of bias,16 inconsistency17 and imprecision18 (online supplementary appendix 2). In particular, G and A+ levels were regarded as moderate-to-high credibility.

Supplemental material

Levels of evidence and strength of suggestions

Levels of evidence were summarised to represent the quality of scientific evidence on the basis of directness of outcome for AD, credibility of meta-analyses and consistency of evidence from clinical trials and/or observational studies: Level A>Level B>Level C (based on the evidence level). Classes of recommendations were made after weighing the benefits against the risks due to specific interventions: Class I (strong recommendation), Class II (weak recommendation) and Class III (not recommended) (figure 2).

Figure 2

Rating levels of evidence and strength of suggestions. Based on the Cochrane Handbook for Systematic Reviews of Interventions for RCTs and the Newcastle–Ottawa Quality Assessment Scale (NOS) for OPSs, we evaluated the quality of eligible studies. The credibility of each result was then categorised into four levels: Good (G level), Acceptable (A± level), Susceptible (S± level) and Poor (P level) according to the score combination of three domains: risk of bias, inconsistency and imprecision. Levels of evidence were summarised, representing the quality of scientific evidence on the basis of directness of outcome (for RCTs), consistency and quality of data from clinical trials and/or observational studies. Classes of suggestions were made after weighing the benefits against the risks due to specific interventions. *Factors rated with ‘level C’ evidence were not considered for recommendation in the present study.

Statistical analyses

The multivariable-adjusted risk estimates and 95% confidence intervals (CI) were log-transformed and combined using random models (DerSimonian–Laird method).19 Sensitivity analyses excluding odd ratios (ORs) reported by some OPSs were performed because ORs tend to overestimate the effect size compared with the relative risk (RR), particularly when the incidence is not small. A 95% prediction interval (PI) was calculated to better evaluate the precision of the result.20 Heterogeneity was assessed by Q test and quantified by the I2 metric.21 The source of heterogeneity was explored via sensitivity analyses, meta-regression and subgroup analyses. The robustness of the results was examined by excluding those rated as at a higher risk of bias. Publication bias was assessed following two steps: (1) testing the symmetry of the funnel plot by the Egger method22; and (2) determining whether any asymmetry was due to publication bias via enhanced-contour funnel plots after the trim-and-fill method.23 The meta-regression and publication bias test were conducted only when at least 10 studies were available. The “metagen”, “metabias” and “trimfill” packages in R 3.4.3 software ( were used to perform all the analyses.

Additionally, multiple subgroup and sensitivity analyses were conducted to take into account the following cases where results might be biased. First, 82% of studies recruited people without dementia at baseline and only 17% specifically constrained the population to those with normal cognition. Notably, inclusion of individuals with mild cognitive impairment, who might be at a prodromal stage of AD, resulted in a degree of misclassification bias, especially when the population was at an advanced age and was insufficiently followed. Thus, subgroup analyses according to the cognitive status at baseline (free of dementia vs cognitively normal), sufficiency of follow-up (online supplementary appendix 1) and life stage were performed. Second, it was often clinically difficult to distinguish mixed AD (coexistence of AD and vascular dementia (VD)) from VD among elderly people, especially when the pathological evidence is often unavailable and the individual has a history of stroke. Thus, to examine the influence of potential misclassification bias, subgroup analyses based on AD outcomes (all AD vs probable or pure AD (p-AD) defined as AD without VD or cerebrovascular disease (CVD)) were performed. Third, sensitivity analyses excluding studies with high attrition rates and poor generalisability (online supplementary appendix 1) were conducted.

Patient involvement

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community. No evaluation was undertaken to determine whether the studies included in the review had any patient involvement.


Figure 1 shows the flow diagrams of the study selection process for OPSs (figure 1A) and RCTs (figure 1B). The search yielded 33 145 and 11 531 records for OPSs and RCTs, respectively. After integration with the AlzRisk database and website, a total of 243 OPSs and 153 completed RCTs were finally included. Evidence-based profiles were constructed (online supplementary appendix 3 & 4). The global distribution of studies eligible for the systematic review and their characteristics are shown in figure 1C. The sources of bias for the current evidence profile mainly consisted of generalisability, attrition and misclassification for OPSs and performance bias, incomplete outcome data, inadequate allocation concealment and selective outcome reporting for RCTs (online supplementary appendix figure 1).

Meta-analyses were conducted for 134 risk factors (online supplementary appendix 5). A total of 43 factors showed significant associations with the risk of AD, among which 80% were identified as significantly modifying the risk by at least 25% (figure 3A). Indicating the credibility of pooled results, analyses for eight risk factors (diabetes, orthostatic hypotension, hypertension in midlife, head trauma, stress, depression, midlife obesity and coronary artery bypass grafting (CABG) surgery) and three protective factors (cognitive activity, increased BMI in late life and education) were rated with moderate-to-high level credibility (G, G/A+ or A+ level). In addition, 20 factors were rated at a low-to-moderate level (A+/A− or A− level) and 12 were rated at a very low level (S+, S− or P level) (figure 3B). With good performance in all the domains above, eight factors were highlighted, including depression (A+ level; RR 1.80; 95% CI 1.34 to 2.42), CABG surgery (G/A+ level; RR 1.71; 95% CI 1.04 to 2.79), diabetes mellitus (G level; RR 1.69; 95% CI 1.51 to 1.89), stress (G/A+ level; RR 1.56; 95% CI 1.19 to 2.04), hypertension in midlife (G/A+ level; RR 1.38; 95% CI 1.29 to 1.47), head trauma (G/A+ level; RR 1.35; 95% CI 1.18 to 1.54), cognitive activity (A+ level; RR 0.50; 95% CI 0.39 to 0.63) and more formal schooling years (>6 to 15 years) (G level; RR 0.49; 95% CI 0.40 to 0.62) (figure 3C). Additionally, another 91 items were found to impart no influence on the risk of AD, but mostly with low levels of credibility, except for late-life hypertension (G level, RR 0.96; 95% CI 0.79 to 1.17) (online supplementary appendix figure 2).

Figure 3

Risk of bias profile, meta-analysis results, sample size (figure 3A), credibility rating (figure 3B) and summary (figure 3C) for 43 significant modifiable risk factors based on observational prospective studies. When the mean score (for each bias domain) ≤0.5 was regarded as possibly moderate-to-high risk, analyses for 79% of factors had problems of generalisability, 60% for high attrition, 48% for insufficient follow-up, 40% for reverse causality, 8% for confounding bias and 6% for assessment of exposure. For a summary of the effect, a total of 43 factors showed significant associations with AD risk; 26 risk factors and eight protective factors were identified that modify the risk by at least 25% (figure 3A). For credibility of the pooled results, 11 factors were rated at a moderate-to-high level (G, G/A+ or A+ level), 20 were rated at a low-to-moderate level (A+/A− or A− level) and 12 were rated at a very low level (S+, S− or P level) (figure 3B). With good performance in all the domains above, eight risk factors are highlighted (figure 3C). AD, Alzheimer’s disease; BMD, bone mineral density; BMI, body mass index; CVD, cerebrovascular disease; DBP, diastolic blood pressure; HSV, herpes simplex virus; IMT, intima-media thickness; NSAIDs, non-steroidal anti-inflammatory drugs; SHBG, sex hormone binding globulin.

For RCTs, 29 meta-analyses covering 11 interventions were conducted (online supplementary appendix 6). Three interventions, including total homocysteine (tHcy)-lowering treatment (using folic acid, vitamin B12 and vitamin B6), cocoa flavanol and physical activity showed significant associations with AD or cognitive endpoints. For the directness of the outcomes, only five meta-analyses (involving acetylcholinesterase inhibitor, antihypertensive treatment, non-steroidal anti-inflammatory drugs (NSAIDs), hormone replacement therapy and ginkgo biloba) examined associations with AD (figure 4A). For the levels of credibility, nine meta-analyses were rated at a moderate-to-high level (G, G/A+ or A+ level), three were rated at a low-to-moderate level (A+/A− or A− level) and 17 were rated at a very low level (S+, S− or P level) (figure 4B). The overall evaluation highlighted two interventions that seemed promising (figure 4C): physical exercise (mini-mental state examination (MMSE), standardised mean difference (SMD) 0.28, 95% CI 0.07 to 0.50 and AD assessment scale cognition, SMD 0.25, 95% CI 0.08 to 0.41) and tHcy-lowering treatment (MMSE, SMD 0.09, 95% CI 0.02 to 0.15) (online supplementary appendix figure 3). Notably, oestrogen therapy was associated with an increase in the risk of dementia (G level).

Figure 4

Risk of bias profile, meta-analysis results, sample size (figure 4A), credibility rating (figure 4B) and summary (figure 4C) for 11 interventions based on randomised controlled trials. When the mean score (for each bias domain) ≤0.5 was regarded as possibly moderate-to-high risk, 17.2% meta-analyses had problems of inadequate concealment of allocations, 27.6% for performance bias, 3.4% for detection bias, 24.1% for incomplete outcome data, 13.8% for selective outcome reporting and 31% for other sources of bias. For the significance of the pooled results, six meta-analyses showed significant associations (figure 4A). For credibility of the pooled results, nine meta-analyses were rated at a moderate-to-high level (G, G/A+ or A+ level), three at a low-to-moderate level (A+/A− or A− level) and 17 at a very low level (S+, S− or P level). Specifically, moderate-to-high credibility of results showed little benefit on the risk of Alzheimer's disease from acetycholinesterase inhibitors, antihypertensive agents in late life, oestrogen therapy, and DHA+EPA supplementation. No robust conclusion could be reached for non-steroidal anti-inflammatory drugs, ginkgo biloba, cocoa flavanol and cognitive training. For directness of outcomes, five meta-analyses examined the associations with AD (figure 4B). Although none showed a good performance in all the above domains, two interventions (physical exercise and total homocysteine-lowering treatment) seem more promising than others (figure 4C).

The significance and the effect size minimally changed for most factors after excluding ORs (online supplementary appendix figure 4). No influences of publication bias on the pooled results were identified (online supplementary appendix 5). The sources of heterogeneity were explored. For diabetes (n=14, I2=65%), the percentage of women explained 39% heterogeneity (p=0.008), which might be attributed to inclusion of two high-risk-of-bias studies24 25 that explored associations only for men. The mean age at baseline explained most heterogeneity for hypertension (p=0.0003) and BMI (p=0.091, τ2=0). No influences of lowering the heterogeneity (I2 <10%) via sensitivity analyses on the pooled results were found for current smoking, systolic blood pressure, education and depression. The influence of risk of bias might be low for depression while smoking and stroke were vulnerable to sources of bias due to misclassification, attrition and generalisability (online supplementary appendix figure 5).

Twenty-one evidence-based suggestions with different levels of evidence (11 with Level A and 10 with Level B) and strength of suggestions (19 with Class I and two with Class III) are listed in table 1. Specifically, Class I suggestions were for 19 factors, including 10 factors with Level A evidence (cognitive activity, hyperhomocysteinaemia, increased BMI in late life, depression, stress, diabetes, head trauma, hypertension in midlife, orthostatic hypotension and education) and nine factors with Level B evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, CVD, frailty, atrial fibrillation and vitamin C) (figure 5). Two factors were not recommended (Class III): oestrogen replacement therapy (Level A) and acetylcholinesterase inhibitors (Level B) (online supplementary appendix 7 & appendix figure 6). Six factors (diastolic blood pressure management, NSAID use, social activity, osteoporosis, pesticide exposure and silicon from drinking water) were rated as Level C low-strength evidence, with the recommendation that their relationships with AD be confirmed in future studies.

Figure 5

Distribution of modifiable factors with Class I recommendation throughout the course of life. Class I suggestions (benefit >>risk due to intervention) risk factors include 10 factors with Level A evidence (cognitive activity, hyperhomocysteinaemia, increased BMI in late life, depression, stress, diabetes, head trauma, hypertension in midlife, orthostatic hypotension and education) and 9 factors (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, CVD, frailty, atrial fibrillation and vitamin C) with Level B evidence. The x axis represents the mean age of the total sample (solid circle) with a range of mean age (short horizontal line) for observational prospective studies included. The y axis represents the summary relative risk (RR). AD, Alzheimer’s disease; OH, orthostatic hypotension; CVD, cerebrovascular disease; IMT, intima-media thickness.

Table 1

Guideline for prevention of AD: preliminary clinical suggestions*


Our systematic review and meta-analysis identified a total of 21 evidence-based suggestions that can be used in life-course practices to prevent AD. Nineteen were regarded as ‘strong suggestions’, nine of which were rated with Level A evidence (table 1). Nearly two-thirds of these suggestions target vascular risk factors and lifestyle, strengthening the importance of keeping a good vascular condition and maintaining a healthy lifestyle for preventing AD.

Strengths and weaknesses of this study

This is the most comprehensive and large-scale systematic review and meta-analysis for AD prevention to date. The evidence-based suggestions are constructed by integrating a large amount of evidence from both OPSs and RCTs. Sources of bias and robustness of evidence were thoroughly assessed and secondary analyses were used to explore their influences, guaranteeing the objectivity and transparency of our findings. Furthermore, the outcome of OPSs was confined to AD dementia, given that the heterogeneity of endpoints might complicate the profile and downgrade the credibility of the evidence because: (1) observational studies are more vulnerable to sources of bias than RCTs, even though a rigorous procedure was employed to grade the evidence; (2) non-AD dementia accounts for roughly 30% of incident dementia (online supplementary appendix figure 7) and the false positive rate for diagnosis of mild cognitive impairment is fairly common.26 Some caveats should also be emphasised. Observational studies cannot indicate causal relationships and RCTs may not be generalisable beyond the specific sample, intervention, dose and duration studied. Classification of the available evidence including assessment of potential biases requires subjective judgement. The values of the current suggestions might be confined by geographic variability, definition of exposure and prevalence of risk factors at the population level. Some important factors of all-cause dementia were inadequately investigated for AD, such as social determinants27 and frailty,28 and more high-quality prospective studies are warranted to bridge this gap. AD is challenging to study. The neurobiology of AD begins at least 15 years before symptoms appear. Tools such as amyloid and tau PET scanning are available to characterise the neuropathology at any stage, but it is impractical to include such assessments in large observational studies; without biomarker data, misclassification is unavoidable and several conclusions may be challenged by studies in the near future. Despite these challenges, this systematic review and meta-analysis can suggest recommendations to guide clinicians, even as the field perseveres with additional studies. These evidence-based suggestions must be presented in the context of the limitations of the studies and continuing uncertainty among investigators. Finally, the present study did not register and the protocol can be found in online supplementary appendix 8.

Strengths and weaknesses in relation to other studies

Notably, tHcy-lowering treatment seems the most promising intervention for AD prevention, in agreement with a recent report.29 The Lancet Commission on dementia has recently proposed nine potentially modifiable risk factors of all-cause dementia. However, these suggestions might not be directly applicable to AD, bearing in mind that the heterogeneity of endpoints complicates the profile and reduces the credibility of evidence for AD prevention. Our study generated more evidence-based suggestions associated with a decreased risk of AD, filling this gap in the field.

Meaning of the study

The hypotheses for the underlying mechanisms may include brain reserve theory, the hypoperfusion hypothesis, one-carbon methabolism, hypomethylation theory, inflammation and the oxidative stress hypothesis. The combination of multiple recommendations is most likely the best approach to delay the onset of AD, as indicated by the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER).30 On the basis of this paper, future clinical trials should focus on exploring the best combination of recommendations with Class I recommendation and Level A evidence to prevent AD using larger samples, particularly in real-world settings. These evidence-based suggestions should be particularly noted by non-demented but high-risk individuals (eg, people with AOPEε4, a high polygenic score, a family history of dementia or amyloid-positive evidence31) and family doctors to give optimal recommendations to their patients in terms of what they might do to get the best protection against AD.

Future research

For OPSs, low participation rates (cognitive activity and stroke), high attrition (stroke, smoking, alcohol drinking and hypertension) and follow-up insufficiency (stroke and smoking) should be specifically highlighted in future prospective studies. Reverse causality might bias the association with late life obesity.32 It is unclear whether reverse causality exists for other potential factors such as frailty, social isolation and sleep disorders. Investigation and comparison of important characteristics of those who refused to participate or were lost during follow-up might be a good method to guarantee optimised validity. Subgroup effects exist due to the characteristics of the sample (eg, age, gender,33 APOEε4 status34 and medication compliance34) or exposure (eg, type, dose and duration). For RCTs, choosing the suitable population might be the key to determining whether an intervention can work. The optimal time window also matters,35 especially considering that benefits were weak for those with a clinical diagnosis of dementia.36 Generalisablity should be further optimised, such as recruiting larger samples from community-dwelling individuals and searching for methods to lower dropout rates. Well-designed clinical trials are needed to verify the effects on AD of several promising interventions, including sleep improvement, smoking cessation, antidepression management and antidiabetic agents.


Twenty-one clinical evidence-based suggestions are proposed, offering clinicians and stakeholders an evidence-based guideline for AD prevention. With credible though inconclusive evidence, the suggestions targeted 10 risk factors including diabetes, hyperhomocysteinaemia, poor BMI management, reduced education, hypertension in midlife, orthostatic hypotension, head trauma, less cognitive activity, stress and depression. This study provides an advanced and contemporary survey of the evidence, suggesting that more high-quality OPSs and RCTs are urgently needed to strengthen the evidence base for uncovering more promising approaches to preventing AD.


The authors thank Professor Michael M Weiner and Dr Yu-Tzu Wu for critical review.



  • Twitter @na, @martindragoncn

  • J-TY, WX and C-CT contributed equally.

  • Contributors JTY and BV conceived and designed the study. JTY, WX, CCT, HFW, MST and JQL selected the articles and extracted the data. JTY, WX, C-CT, HFW, M-ST, J-QL, XHH, YW, LT and LT proofread the data. JTY, WX, C-CT and AP analysed the data. WX and CCT generated the figures. JTY, WX, CCT wrote the first draft of the manuscript. JTY, WX, C-CT, SA, JS, EE, CZ, JJ, AP, LF, EHK, YJW, VM, JT, GS, PSA, QD, and BV interpreted the data and contributed to the writing of the final version of the manuscript. All authors agreed with the results and conclusions and approved the final draft.

  • Funding This study was supported by grants from the National Key R&D Program of China (2018YFC1314702), Shanghai Municipal Science and Technology Major Project (No. 2018SHZDZX03) and ZHANGJIANG LAB.

  • Competing interests JTY serves as an associate editor-in-chief for Annals of Translational Medicineand is senior editor for Journal of Alzheimer’s Disease. SA has received grants from Europe, Ipsen, and France Alzheimer, served as a consultant for Ipsen, Pierre Fabre, Lilly, Nestlé, Sanofi and Servier, and received non-financial support from Biogen, Nutrition Santé, Pfzer and Icon, and other support from the AMPA Association. GS has received clinical trial support from Lilly and Roche in DIAN-TU, TauRx Therapeutics (TauRx) and Lundbeck; has been a data safety monitoring board (DSMB) member of ADCS, ATRI, API and Eisai; and has been a scientific adviser to Affiris, Boehringer Ingelheim, Lilly, Roche, Servier, Sanofi, Schwabe, Takeda and TauRx. PSA has received grants from the US Alzheimer’s Association, Janssen, Lilly, the US National Institute on Aging and Toyama; and consulting fees from Abbott, Abbvie, Amgen, Anavex, AstraZeneca, Biogen Idec, Biotie, Bristol-Myers Squibb, Cardeus, Cohbar, Eisai, Elan, Eli Lilly, Genentech, Ichor, iPerian, Janssen, Lundbeck, Medivation, Merck, NeuroPhage, Novartis, Pfizer, Probiodrug, Roche, Somaxon and Toyama, outside the submitted work. BV reports grants from Pierre Fabre, Avid, Exonhit, AbbVie, Lilly, Lundbeck, MSD, Otsuka, Regenron, Sanofi, Roche, AstraZeneca, LPG Systems, Nestlé and Alzheon, and personal fees from Lilly, Lundbeck, MSD, Otsuka, Roche, Sanofi, Biogen, Nestlé, Transition Therapeutics and Takeda.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles